Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 289

Sort by

Sort Order Select

Journal Articles

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Blood (2024) 144 (21): 2169–2173.

https://doi.org/10.1182/blood.2024025409

Published: 2024

Journal Articles

ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

Blood (2023) 142 (Supplement 1): 4539.

https://doi.org/10.1182/blood-2023-180730

Published: 2023

Journal Articles

Patterns of Graft-Versus-Host Disease (GvHD) Prevention and Management in the Eastern Mediterranean (EM) Region: A Worldwide Network for Blood & Marrow Transplantation (WBMT) Survey

Blood (2023) 142 (Supplement 1): 7029.

https://doi.org/10.1182/blood-2023-182995

Published: 2023

Journal Articles

Cryopreserved Versus Non-Cryopreserved Peripheral Blood Haematopoietic Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma: A Comparative Analysis from the Chronic Malignancies Working Party of EBMT and WBMT

Blood (2023) 142 (Supplement 1): 1034.

https://doi.org/10.1182/blood-2023-182808

Published: 2023

Journal Articles

Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis

Gerard Socié, Dietger Niederwieser, Nikolas von Bubnoff, Mohamad Mohty, Jeff Szer, Reuven Or, James Garrett, Anirudh Prahallad, Celine Wilke, Robert Zeiser

Blood (2023) 141 (22): 2771–2779.

https://doi.org/10.1182/blood.2022018579

Published: 2023

Includes: Supplemental data

Journal Articles

International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation

Blood (2022) 140 (Supplement 1): 5225–5227.

https://doi.org/10.1182/blood-2022-165010

Published: 2022

Journal Articles

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Blood (2022) 140 (Supplement 1): 2126–2129.

https://doi.org/10.1182/blood-2022-157684

Published: 2022

Journal Articles

Improvements in AML Treatment Outcomes By Twinning at the Instituto De Prevision Social Hospital in Paraguay

Cristobal Augusto Frutos Ortiz, Lidiane Andino, Alfredo Reinaldo Quiroz, Dietger Niederwieser, Maria Elvira Enciso, Aline Nicole Paats, Victor Salinas

Blood (2022) 140 (Supplement 1): 8936–8937.

https://doi.org/10.1182/blood-2022-170477

Published: 2022

Journal Articles

Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)

Blood (2022) 140 (Supplement 1): 947–949.

https://doi.org/10.1182/blood-2022-159412

Published: 2022

Journal Articles

An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Molly Tokaz, Helen Baldomero, Andrew J Cowan, Wael Saber, Hildegard T. Greinix, Mickey Koh, Nicolaus Kröger, Mohamad Mohty, Sebastian Galeano, Shinichiro Okamoto, Naeem A. Chaudhri, Amado J Karduss, Fabio Ciceri, Vergilio Rensi Colturato, Selim Corbacioglu, Alaa M. Elhaddad, Lisa Force, Cristobal Augusto Frutos Ortiz, Andres Gomez-De Leon, Nada Hamad, Nelson Hamerschlak, Naya He, Aloysius YL Ho, Xiao-Jun Huang, Benjamin Jacobs, Heeje Kim, Minako Iida, Leslie E. Lehmann, Régis Peffault de Latour, Mary-Elizabeth M. Percival, Walid Rasheed, Kirk R. Schultz, Adriana Seber, Bor-Sheng Ko, Anderson Simione, Alok Srivastava, Jeff Szer, William A. Wood, Yoshihisa Kodera, Arnon Nagler, John A Snowden, Daniel J. Weisdorf, Jakob R. Passweg, Marcelo C Pasquini, Anna Sureda, Yoshiko Atsuta, Mahmoud Aljurf, Dietger Niederwieser, Martina Perdomo

Blood (2022) 140 (Supplement 1): 8146–8149.

https://doi.org/10.1182/blood-2022-158338

Published: 2022

Journal Articles

Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers

Blood (2022) 140 (Supplement 1): 4839–4842.

https://doi.org/10.1182/blood-2022-164619

Published: 2022

Journal Articles

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Blood (2022) 140 (12): 1345–1377.

https://doi.org/10.1182/blood.2022016867

Published: 2022

Journal Articles

Diagnostic Red Blood Cell Distribution Width As a Prognostic Factor in Acute Myeloid Leukemia

Vladan Vucinic, Leo Ruhnke, Katja Sockel, Maximilian Alexander Röhnert, Donata Backhaus, Dominic Brauer, Georg-Nikolaus Franke, Dietger Niederwieser, Martin Bornhäuser, Christoph Rollig, Uwe Platzbecker, Sebastian Schwind, Madlen Jentzsch

Blood (2021) 138 (Supplement 1): 1227.

https://doi.org/10.1182/blood-2021-145497

Published: 2021

Journal Articles

Applicability of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) to Predict Outcomes of Acute Myeloid Leukemia Patients Older Than 60 Years Undergoing Non-Myeloablative Allogeneic Stem Cell Transplantation

Donata Backhaus, Madlen Jentzsch, Dominic Brauer, Julia Schulz, Vladan Vucinic, Georg-Nikolaus Franke, Dietger Niederwieser, Uwe Platzbecker, Sebastian Schwind

Blood (2021) 138 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2021-150712

Published: 2021

Journal Articles

Differential Prognostic Relevance of Measurable Residual Disease in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in First Versus Second Morphologic Remission

Madlen Jentzsch, Johannes Küpper, Dominic Brauer, Donata Backhaus, Julia Schulz, Georg-Nikolaus Franke, Vladan Vucinic, Dietger Niederwieser, Uwe Platzbecker, Sebastian Schwind

Blood (2021) 138 (Supplement 1): 416.

https://doi.org/10.1182/blood-2021-144794

Published: 2021

Journal Articles

Prognostic Impact of Nutritional Status at Diagnosis and Weight Changes in Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

Dominic Brauer, Donata Backhaus, MD, Vladan Vucinic, MD, Dietger Niederwieser, MD PhD, Uwe Platzbecker, Madlen Jentzsch, MD, Sebastian Schwind, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-134187

Published: 2020

Journal Articles

Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study

John Mascarenhas, MD, Rami S. Komrokji, MD, Michele Cavo, Bruno Martino, MD, Dietger Niederwieser, MD PhD, Andreas Reiter, MD, Bart L. Scott, MD, Maria R. Baer, MD, Ronald Hoffman, MD, Olatoyosi Odenike, MD, Laurie Sherman, BSN, Souria Dougherty, BS, MBA, Tymara Berry, MD, Faye Feller, MD, Libo Sun, PhD, Ying Wan, PhD, Aleksandra Rizo, MD PhD, Fei Huang, PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138905

Published: 2020

Journal Articles

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140403

Published: 2020

Journal Articles

The Incidence of Mastocytosis in Patients with Unclear Cytopenia and/or Leucocytosis: The Hryd Study

Hannah Seemann, Nadja Jaekel, Susann Schulze, MD, Juliane Grimm, MD, Ole Vollstaedt, MD, Anja Haak, PhD, Dietger Niederwieser, MD PhD, Claudia Wickenhauser, MD, Haifa Kathrin Al-Ali, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-139311

Published: 2020

Journal Articles

Totality of Scientific Evidence in the Development of ABP 798, a Biosimilar to Rituximab

Dietger Niederwieser, MD PhD, Caroline Hamm, MD, Patrick Cobb, MD, Theingi Thway, PhD, Cecily Forsyth, FRACP, FRCPA, MBBS, Alessandra Tucci, MD, Vincent Delwail, Roman Hajek, MD PhD, Vladimir Hanes, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-142723

Published: 2020

NARROW

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

Patterns of Graft-Versus-Host Disease (GvHD) Prevention and Management in the Eastern Mediterranean (EM) Region: A Worldwide Network for Blood & Marrow Transplantation (WBMT) Survey

Cryopreserved Versus Non-Cryopreserved Peripheral Blood Haematopoietic Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma: A Comparative Analysis from the Chronic Malignancies Working Party of EBMT and WBMT

Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis

International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Improvements in AML Treatment Outcomes By Twinning at the Instituto De Prevision Social Hospital in Paraguay

Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)

An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Diagnostic Red Blood Cell Distribution Width As a Prognostic Factor in Acute Myeloid Leukemia

Applicability of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) to Predict Outcomes of Acute Myeloid Leukemia Patients Older Than 60 Years Undergoing Non-Myeloablative Allogeneic Stem Cell Transplantation

Differential Prognostic Relevance of Measurable Residual Disease in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in First Versus Second Morphologic Remission

Prognostic Impact of Nutritional Status at Diagnosis and Weight Changes in Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study

Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study

The Incidence of Mastocytosis in Patients with Unclear Cytopenia and/or Leucocytosis: The Hryd Study

Totality of Scientific Evidence in the Development of ABP 798, a Biosimilar to Rituximab

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only